Abstract: Disclosed herein include methods, compositions, and kits suitable for use in treatment and/or prevention of RNA viral infections. In some embodiments, the method comprises modulation of host factors related to RNA viral infection using compounds, compositions and kits disclosed herein. There are provided, some embodiments, compounds modulating host factors that govern SARS-CoV-2 replication. Disclosed herein include the use of compounds, compositions and kits disclosed herein to prevent and/or treat SARS-CoV-2 infection, for example by modulating the SARS-CoV-2 life cycle.

Abstract: This application relates to the modulation of host cell factors required for influenza virus replication. The application relates to compounds, including nucleic acid compounds (such as, e.g., small interfering RNAs (siRNAs)) and small molecules, that target human host cell factors involved in influenza virus replication, and the use of such compounds for modulating influenza virus replication and as antiviral agents. The application also relates to methods of treating an influenza virus infection and methods of treating or preventing a symptom or disease associated with influenza virus infection, comprising administering to a subject a composition comprising a compound, such as a nucleic acid compound (e.g., an siRNA) or small molecule, that targets a human host cell factor involved in influenza virus replication.

Abstract: This application relates to the modulation of host cell factors required for influenza virus replication. The application relates to compounds, including nucleic acid compounds (such as, e.g., small interfering RNAs (siRNAs)) and small molecules, that target human host cell factors involved in influenza virus replication, and the use of such compounds for modulating influenza virus replication and as antiviral agents. The application also relates to methods of treating an influenza virus infection and methods of treating or preventing a symptom or disease associated with influenza virus infection, comprising administering to a subject a composition comprising a compound, such as a nucleic acid compound (e.g., an siRNA) or small molecule, that targets a human host cell factor involved in influenza virus replication.

Abstract: The invention provides methods for modulating insulin signaling pathway and methods for treating insulin resistance. The methods employ agents which modulate FOXO1 subcellular localization. The invention also provides methods of screening for compounds that modulate insulin signaling related activities such as gluconeogenesis and cell proliferation.

Abstract: This invention provides novel AP-1 modulatory polypeptides. The invention also provides methods for screening modulators of AP-1 transcription factor activities. The methods comprise first screening test agents for modulators of an AP-1-modulatory polypeptide and then further screening the identified modulating agents for modulators of AP-1 transcription factor activities. The invention further provides methods and pharmaceutical compositions for modulating AP-1 transcription factor activities in a cell and for treating diseases and conditions mediated by abnormal cellular proliferation.

Abstract: This invention provides cellular regulators of antitumor agent apratoxin A. The invention also provides methods for identifying novel antitumor compounds using these cellular regulators of apratoxin A. The methods comprise first screening test agents for modulators of a cellular regulator of apratoxin A and then further screening the identified modulating agents for antitumor activities. The invention further provides methods and pharmaceutical compositions for treating tumors in a subject.

Abstract: This invention provides novel polypeptides that modulate activities of the replication and transcription activator (RTA) of Kaposi's sarcoma-associated herpesvirus (KSHV). The invention also provides methods for screening modulators of RTA activities. The methods comprise first screening test agents for modulators of an RTA-modulatory polypeptide and then further screening the identified modulating agents for modulators of RTA activities. The invention further provides methods and pharmaceutical compositions for treating diseases and conditions associated with infections of gammaherpesviruses.

Abstract: This invention provides novel NF-AT-modulatory polypeptides. The invention also provides methods for screening modulators of NF-AT. The methods comprise first screening test agents for modulators of an NF-AT-modulatory polypeptide and then further screening the identified modulating agents for modulators of NF-AT. The invention further provides methods and pharmaceutical compositions for modulating NF-AT bioactivities in a cell and for treating diseases and conditions mediated by abnormal NF-AT activities.

Abstract: This invention provides novel Epo-modulating polypeptides. The invention also provides methods for screening modulators of Epo expression. The methods comprise first screening test agents for modulators of an Epo-modulating polypeptide and then further screening the identified modulating agents for modulators of Epo expression. The invention further provides methods and pharmaceutical compositions for modulating Epo expression in cells and for treating diseases and conditions due to Epo deficiency.

Abstract: This invention provides novel p53 modulatory polypeptides. The invention also provides methods for screening modulators of p53. The methods comprise first screening test agents for modulators of a p53-modulatory polypeptide and then further screening the identified modulating agents for modulators of p53. The invention further provides methods and pharmaceutical compositions for modulating p53 bioactivities in a cell and for treating diseases and conditions mediated by abnormal cellular proliferation.

Abstract: This invention provides novel AP-1 modulatory polypeptides. The invention also provides methods for screening modulators of AP-1 transcription factor activities. The methods comprise first screening test agents for modulators of an AP-1-modulatory polypeptide and then further screening the identified modulating agents for modulators of AP-1 transcription factor activities. The invention further provides methods and pharmaceutical compositions for modulating AP-1 transcription factor activities in a cell and for treating diseases and conditions mediated by abnormal cellular proliferation.